Back to top
more

The Joint (JYNT)

(Delayed Data from NSDQ)

$17.06 USD

17.06
70,862

+0.61 (3.71%)

Updated May 14, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (48 out of 250)

Industry: Medical - HMOs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

The Joint Corp. (JYNT) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

The Joint Corp. (JYNT) delivered earnings and revenue surprises of 225.00% and 7.76%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate The Joint Corp. (JYNT) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

The Joint Corp. (JYNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Should You Hold Onto Anthem (ANTM) in Your Portfolio?

by Zacks Equity Research

A solid positioning in an ever-growing industry along with strong fundamentals make Anthem (ANTM) a good fit for investment gains.

Magellan (MGLN) Unit Launches Solution to Improve Behavioral Care

by Zacks Equity Research

Magellan's (MGLN) unit - Magellan Healthcare - together with NeuroFlow, introduces a collaborative care management solution in a bid to ease the behavioral health treatment process.

Why Should You Hold Molina Healthcare (MOH) in Your Portfolio?

by Zacks Equity Research

Riding high on strategic measures and membership growth, Molina Healthcare (MOH) holds enough potential to reap benefits for investors.

Cigna's (CI) 2022 Expansion Plans to Boost MA Customer Base

by Zacks Equity Research

Cigna (CI) unveils enhanced health plans for its customers to opt for in the 2022 Medicare AEP period. The company will foray into newer counties and states to offer enhanced health outcomes.

Here's Why You Should Retain Cigna (CI) Stock for Now

by Zacks Equity Research

Cigna (CI) is benefiting on the back of robust segmental performances and well-diversified healthcare suite. A strong partner network throughout U.S. is an added advantage.

UnitedHealth (UNH) Unit to Offer Better Pharmacy Care in Arizona

by Zacks Equity Research

Genoa, which comes under UnitedHealth Group's (UNH) subsidiary Optum, opens a pharmacy in one of Arizona's clinics for offering enhanced pharmacy care for behavioral health patients.

Humana (HUM), Kelsey-Seybold Clinic Tie Up for Better Healthcare

by Zacks Equity Research

Humana (HUM) inks a deal with Kelsey-Seybold Clinic in Houston to offer its Humana Medicare Advantage HMO members enriched healthcare facilities.

Why Should You Hold Centene (CNC) in Your Portfolio Now?

by Zacks Equity Research

Riding high on strategic initiatives and operational excellence, Centene (CNC) holds potential to reap benefits for investors.

    Humana (HUM), Curant Health Team Up to Aid Chronic Patients

    by Zacks Equity Research

    Humana (HUM) inks a deal with Curant Health to offer its members with chronic diseases enriched healthcare facilities.

    Here's Why You Should Hold Molina Healthcare (MOH) Stock Now

    by Zacks Equity Research

    Riding high on its rising membership, a healthy revenue stream and restructuring measures, Molina Healthcare (MOH) holds potential to reap benefits for investors.

    Encompass Health (EHC) Opens Hospital, Boosts Florida Footprint

    by Zacks Equity Research

    Encompass Health (EHC) opens an inpatient rehabilitation hospital in Pensacola, FL aimed at providing improved health outcomes across the state.

    Why Should You Hold onto Anthem (ANTM) in Your Portfolio?

    by Zacks Equity Research

    Riding high on growing revenues, solid guidance and strategic initiatives, Anthem (ANTM) holds potential to reap benefits for investors.

    Cigna (CI) Hikes Buyback Authorization, Boosts Shareholder Value

    by Zacks Equity Research

    Cigna's (CI) board raises share buyback authorization in an effort to support prudent capital deployment.

    Humana (HUM) Acquires Remaining Shares at Kindred at Home

    by Zacks Equity Research

    Humana (HUM) closes its Kindred at Home buyout to bolster its home health and hospice business.

    The Joint Corp. (JYNT) is an Incredible Growth Stock: 3 Reasons Why

    by Zacks Equity Research

    The Joint Corp. (JYNT) is well positioned to outperform the market, as it exhibits above-average growth in financials.

    The Joint Corp. (JYNT) Q2 Earnings and Revenues Top Estimates

    by Zacks Equity Research

    The Joint Corp. (JYNT) delivered earnings and revenue surprises of 260.00% and 15.01%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

    The Joint Corp. (JYNT) Moves to Buy: Rationale Behind the Upgrade

    by Zacks Equity Research

    The Joint Corp. (JYNT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

    The Joint Corp. (JYNT) Reports Next Week: Wall Street Expects Earnings Growth

    by Zacks Equity Research

    The Joint Corp. (JYNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Humana (HUM) to Announce Q2 Earnings: Here's What to Expect

    by Zacks Equity Research

    Humana's (HUM) second-quarter earnings results to reflect a steep expense level, partly offset by better revenues.

    What's in the Cards for Centene's (CNC) Earnings in Q2?

    by Zacks Equity Research

    Centene's (CNC) second-quarter results are likely to reflect escalated expenses, partly offset by improved revenues.

    UnitedHealth (UNH) to Post Q2 Earnings: What's in the Offing?

    by Zacks Equity Research

    UnitedHealth's (UNH) Q2 revenues are likely to have grown on higher membership. Nevertheless, COVID-related costs and steep expenses due to investment in growth and innovation might have hurt earnings.

    Srijita Guha headshot

    3 Health Insurers Poised to Beat Earnings Estimates in Q2

    by Srijita Guha

    Health insurers' second-quarter 2021 earnings results are likely to reflect higher premiums, partly offset by elevated operating costs.

    Anthem (ANTM) Buys MMM & Other Units From InnovaCare Health

    by Zacks Equity Research

    Anthem (ANTM) purchases subsidiaries of InnovaCare Health to facilitate better health outcomes across Puerto Rico.